282 related articles for article (PubMed ID: 21109842)
1. Is pharmacogenetic CYP2D6 testing useful?
Vetti HH; Molven A; Eliassen AK; Steen VM
Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
[TBL] [Abstract][Full Text] [Related]
2. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
Sjöqvist F; Eliasson E
Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
[TBL] [Abstract][Full Text] [Related]
4. [Status of and perspectives on psychiatric genomic medicine].
Mors NP; Børglum AD
Ugeskr Laeger; 2005 May; 167(20):2191-3. PubMed ID: 15987082
[No Abstract] [Full Text] [Related]
5. Personalized medicine in psychiatry: new technologies and approaches.
Costa e Silva JA
Metabolism; 2013 Jan; 62 Suppl 1():S40-4. PubMed ID: 23018148
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics and psychoactive drug therapy: ready for the patient?
Steimer W
Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233
[TBL] [Abstract][Full Text] [Related]
7. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Practical issues related to medication selection.
Smoller JW
CNS Spectr; 2006 Mar; 11(3 Suppl 3):5-7. PubMed ID: 17760223
[No Abstract] [Full Text] [Related]
8. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
9. Current applications of clinical genetic testing for psychiatric practice.
Mrazek DA
Minn Med; 2007 Jan; 90(1):42-3. PubMed ID: 17305105
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient.
Paulzen M; Tauber SC; Kirner-Veselinovic A; Gründer G
J Clin Psychiatry; 2011 Nov; 72(11):1465-7. PubMed ID: 22127193
[No Abstract] [Full Text] [Related]
12. CYP2D6 genotypes in Puerto Rican psychiatry patients with intolerance of antidepressants and antipsychotics.
Gonzalez-Tejera GM; Corey S
Bol Asoc Med P R; 2009; 101(1):7-12. PubMed ID: 19954080
[TBL] [Abstract][Full Text] [Related]
13. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?
Herbild L; Bech M; Gyrd-Hansen D; Christensen M; Werge T; Nielsen KA
Scand J Public Health; 2011 Mar; 39(2):147-55. PubMed ID: 21257648
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
15. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
16. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry].
Stephan PL; Etzensberger M; Jaquenoud Sirot E
Praxis (Bern 1994); 2006 Apr; 95(17):671-8. PubMed ID: 16686323
[TBL] [Abstract][Full Text] [Related]
18. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
Bousman CA; Jaksa P; Pantelis C
Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
[TBL] [Abstract][Full Text] [Related]
19. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.
Walden LM; Brandl EJ; Tiwari AK; Cheema S; Freeman N; Braganza N; Kennedy JL; Müller DJ
Psychiatry Res; 2019 Sep; 279():111-115. PubMed ID: 29699889
[TBL] [Abstract][Full Text] [Related]
20. Ethnopsychopharmacology and pharmacogenomics.
Silva H
Adv Psychosom Med; 2013; 33():88-96. PubMed ID: 23816866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
